<DOC>
	<DOC>NCT00642057</DOC>
	<brief_summary>Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).</brief_summary>
	<brief_title>Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements</brief_title>
	<detailed_description>The purpose of the protocol is to provide compassionate use of an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).</detailed_description>
	<mesh_term>Movement Disorders</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Tetrabenazine</mesh_term>
	<criteria>Subjects evaluated here at Baylor in the PDCMDC demonstrating need for tetrabenazine treatment. Willing to sign informed consent. Willing to comply with procedures required as part of this study. Those subjects unwilling to comply with study requirements. Subjects unable to give informed consent.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>chorea</keyword>
	<keyword>dyskinesia</keyword>
	<keyword>hyperkinetic</keyword>
</DOC>